Crizotinib in ROS1-rearranged non-small-cell lung cancer.

@article{Shaw2014CrizotinibIR,
  title={Crizotinib in ROS1-rearranged non-small-cell lung cancer.},
  author={Alice Tsang Shaw and S H Ignatius Ou and Yung-jue Bang and David Ross Camidge and Benjamin J. Solomon and Ravi Salgia and Gregory J Riely and Marileila Varella-Garcia and Geoffrey I. Shapiro and Daniel Botelho Costa and Robert C Doebele and Long Phi Le and Zongli Zheng and Weiwei Tan and Patricia Stephenson and S. Martin Shreeve and Lesley M. Tye and James G. Christensen and Keith D. Wilner and Jeffrey T. Clark and Anthony John Iafrate},
  journal={The New England journal of medicine},
  year={2014},
  volume={371 21},
  pages={
          1963-71
        }
}
BACKGROUND Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non-small-cell lung cancers (NSCLCs) that may be susceptible to therapeutic ROS1 kinase inhibition. Crizotinib is a small-molecule tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and another proto-oncogene receptor tyrosine kinase, MET. METHODS We enrolled 50 patients with advanced NSCLC who tested positive for ROS1… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 36 references

Preclinical rationale for use of the clinically available mulThe New England Journal of Medicine Downloaded from nejm.org at EASTERN KENTUCKY

H Yasuda, LL de Figueiredo-Pontes, S Kobayashi, DB. Costa
UNIV on November • 2014

Updated efficacy and safety of the ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC)

SN Gettinger, L Bazhenova, R Salgia
Presented at the Annual Meeting of the American Society of Clinical Oncology, Chicago, May 30–June • 2014

reospecific targeting of MTH 1 by ( S ) - crizo - tinib as an anticancer strategy

KV Huber, E Salah, B Radic
Nature • 2014